Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
Authors: Neeraj Agarwal, Michael Thomas Schweizer, Elena Castro, Arun Azad, Daniel J. George, Jayeta Chakrabarti, Sujata Narayanan, Yiyun Tang, Karim Fizazi